Clinicn Investigator, Assc Prf Cancer Center, Mass General Research Institute

Associate Professor of Medicine Harvard Medical School

Assistant In Medicine Medicine-Hematology/Oncology, Massachusetts General Hospital

MD Harvard Medical School 2008

cancer immunotherapy; cancer treatment resistance; carcinoma non-small-cell lung; drug resistance neoplasm; gene rearrangement; immune checkpoint blockade; lung cancer; physician-patient relations; protein-tyrosine kinases; proto-oncogene proteins c-ret; receptor protein-tyrosine kinases I am the Director of the Center for Thoracic Cancers and Director of Targeted Immunotherapy at the Massachusetts General Hospital. My research focuses on developing novel cancer immunotherapies and immunotherapy combinations. I am the principal investigator of a broad portfolio of first-in-human clinical trials exploring new immunotherapeutic agents. In parallel, I am an active translational researcher addressing problems at the intersection of the clinic and basic science laboratories. My current work focuses on identifying predictive biomarkers of response and resistance to immune checkpoint inhibitors. I am currently a co-leader of the American Cancer Society-SU2C Lung Cancer Dream Team, whose mission is to identify molecular mechanisms of resistance to cancer immunotherapy.